BRAF as a potential therapeutic target in melanoma and other malignancies

Cancer Cell

Volumn 4, Issue 2, 2003, Pages 95-98

  Tuveson, David A ^a,b   Weber, Barbara L ^a,b   Herlyn, Meenhard ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; BCR ABL PROTEIN; CARBOPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ALLELE; ANGIOGENESIS; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DYSPLASTIC NEVUS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA CELL; MISMATCH REPAIR; ONCOGENE; ONCOGENE BRAF; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; TARGET CELL; TISSUE SPECIFICITY;

EID: 0042885906     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00189-2     Document Type: Review

References (29)

1. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A.et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:2002;6997-7000.
2. Chong H., Vikis H.G., Guan K.L. Mechanisms of regulating the Raf kinase family. Cell. Signal. 15:2003;463-469.
3. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 95:2003;625-627.
4. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W.et al. Mutations of the BRAF gene in human cancer. Nature. 417:2002;949-954.
5. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
6. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037.
7. Edmunds S.C., Cree I.A., Di Nicolantonio F., Hungerford J.L., Hurren J.S., Kelsell D.P. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer. 88:2003;1403-1405.
8. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
9. Gorre M.E., Ellwood-Yen K., Chiosis G., Rosen N., Sawyers C.L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:2002;3041-3044.
10. Herlyn M., Satyamoorthy K. Activated ras. Yet another player in melanoma? Am. J. Pathol. 149:1996;739-744.
11. Hingorani S.R., Tuveson D.A. Targeting oncogene dependence and resistance. Cancer Cell. 3:2003;414-417.
12. Hodi F.S., Soiffer R.J., Clark J., Finkelstein D.M., Haluska F.G. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am. J. Clin. Oncol. 25:2002;283-286.
13. Jaiswal R.K., Weissinger E., Kolch W., Landreth G.E. Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90. J. Biol. Chem. 271:1996;23626-23629.
14. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer. genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma Cancer Res. 63:2003;1454-1457.
15. Lazar-Molnar E., Hegyesi H., Toth S., Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine. 12:2000;547-554.
16. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8:2001;219-225.
17. Mercer K.E., Pritchard C.A. Raf proteins and cancer. B-Raf is identified as a mutational target Biochim. Biophys. Acta. 1653:2003;25-40.
18. Metzelaar-Blok J.A., Jager M.J., Moghaddam P.H., van der Slik A.R., Giphart M.J. Frequent loss of heterozygosity on chromosome 6p in uveal melanoma. Hum. Immunol. 60:1999;962-969.
19. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., Meyerson M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62:2002;7001-7003.
20. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J.et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33:2003;19-20.
21. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis. RAF/RAS oncogenes and mismatch-repair status Nature. 418:2002;934.
22. Satyamoorthy K., Li G., Gerrero M.R., Brose M.S., Volpe P., Weber B.L., Van Belle P., Elder D.E., Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63:2003;756-759.
23. Singer G., Oldt R. 3rd, Cohen Y., Wang B.G., Sidransky D., Kurman R.J., Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95:2003;484-486.
24. Takayama T., Ohi M., Hayashi T., Miyanishi K., Nobuoka A., Nakajima T., Satoh T., Takimoto R., Kato J., Sakamaki S., Niitsu Y. Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology. 121:2001;599-611.
25. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., Hauss J., Wittekind C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 52:2003;706-712.
26. Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., Fletcher C.D., Fletcher J.A., Demetri G.D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein. biological and clinical implications Oncogene. 20:2001;5054-5058.
27. Yamashita N., Minamoto T., Ochiai A., Onda M., Esumi H. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology. 108:1995;434-440.
28. Yuen S.T., Davies H., Chan T.L., Ho J.W., Bignell G.R., Cox C., Stephens P., Edkins S., Tsui W.W., Chan A.S.et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 62:2002;6451-6455.
29. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:1998;2997-3007.